Pfizer said the FDA granted priority review to its prostate cancer drug combination application, cutting the review timeline to six months from the standard 10 months.
Back
Pfizer's prostate cancer combo gets FDA priority review in 6 months
Pfizer said Wednesday the U.S. Food and Drug Administration granted priority review to its application seeking expanded approval of its prostate cancer treatment combination, accelerating the regulatory timeline to six months.
The FDA designates priority review for therapies that offer significant advances over existing treatments. The designation shortens the review period to six months from the standard 10 months under the Prescription Drug User Fee Act.
The application covers a combination regimen for prostate cancer, which ranks among the most frequently diagnosed cancers in men. Pfizer did not disclose the specific drug names in the combination or provide clinical trial data in the announcement.
The priority review designation reduces regulatory uncertainty and could accelerate Pfizer's path to expanded market exclusivity for the combination. The FDA is expected to deliver a decision within six months. An approval would broaden Pfizer's oncology portfolio and strengthen its competitive position in the prostate cancer treatment market.
This article is for informational purposes only and does not constitute investment advice.
